RxDoctor Payments Data

Angela McCall Brown, NP

Adult Health · Newark, NJNPI 1417259383

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,426 of the $7,025 with a category attached, or 63.0%. 18 manufacturers reported payments, led by Cvrx, Inc. at 52.0% of the total. 2025 is the largest year on record at $4,171, more than ten times the $128 reported in 2023. Among adult health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,025in general payments, 2019–2025

Across 141 payments — averaging $49.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$4K
  • Abbott$1K
  • Merck$353
  • AstraZeneca$318
  • Novartis$218
  • Astellas Pharma US Inc$190
  • plus $973 from 12 others

What the payments were for

  • Travel & lodging$2,59937%
  • Food & beverage$4,42663%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,025 in reported general payments places this provider in the 95th percentile of 1,135 adult health providers in New Jersey.

See all adult health providers in New Jersey

Medicare billing

Part B allowed, 2024
$3,948
Medicare patients
17
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin26$35,259
EntrestoSacubitril/Valsartan22$24,981
FarxigaDapagliflozin Propanediol15$17,301
EliquisApixaban16$16,788
Torsemide16$333
Carvedilol21$225
Atorvastatin Calcium19$193
Spironolactone12$85
Furosemide15$35

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$115$35,25926 claims
NovartisEntresto$218$24,98122 claims
AstraZenecaFarxiga$318$17,30115 claims
PfizerEliquis$30$16,78816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,135 adult health providers in New Jersey.

Other adult health in Newark

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →